FRANCIS R. CANO, PH.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

BIOMERICA INC

Filing Date Source Excerpt
2001-10-01 Francis R. Cano, Ph.D. has served as a Director of the Company since June 1999. Dr. Cano currently works as a consultant in the biomedical field.
2002-09-30 Francis R. Cano, Ph.D. has served as a Director of the Company since June 1999. Dr. Cano currently works as a consultant in the biomedical field. From 1996 to 1997, Dr. Cano served as Senior Vice President - Biotechnology of BDM, an information technology company. From 1992 to 1996, he served as President and Chief Operating Officer of Aviron, a public biotechnology company focused on developing viral vaccines for disease prevention. Dr. Cano was also involved in developing a vaccine business at a division of American Cynamid Corporation. Dr. Cano also serves on the board of Lancer Orthodontics,Inc. REPORT OF THE AUDIT COMMITTEE The Audit Committee oversees the Company's financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process including the systems of internal controls. In fulfilling its oversight responsibilities, the Committee reviewed the audited financial statements in the Annual Report with management including a discussion of the quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, and the clarity of disclosures in the financial statements. The Committee reviewed with the independent auditors, who are responsible for expressing an opinion on the conformity of those audited financial statements with generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of the Company's accounting principles and such other matters as are required to be discussed with the Committee has discussed with the independent auditors' the auditors' independence from management and the Company including the matters in the written disclosures required by the Independence Standards Board and considered the compatibilty of non-audit services with the auditors' independence. The Committee discussed with the Company's independent auditors the overall scope and plans for their respective audit. The Committee meets with the independent auditors, with and without management present, to discuss the results of their examinations, their evaluations of the Company's internal controls, and the overall quality of the Company's financial reporting. The audit committee met once during the fiscal year ended May 31, 2002.
2005-09-28 Francis R. Cano, Ph.D. 58 1999 Director
2006-09-28 Francis R. Cano, Ph.D., 59, Director. Dr. Cano has served as a Director since June 1999. The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. The Audit Committee members are Mr. Barbieri and Dr. Cano.
2007-09-28 Francis R. Cano, Ph.D., 60, Director. Compensation: $9,050 from stock option awards.
2008-09-29 Francis R. Cano, Ph.D., 61, Director, member of Audit Committee, Member of Compensation Committee. Compensation: No direct payment, but granted options. Director compensation table shows $0 for fees and awards.
2009-09-29 Francis R. Cano, Ph.D. 62 1999 Director, Member of Audit Committee, Member of Compensation Committee The Audit Committee met one time during fiscal 2009. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. DIRECTOR COMPENSATION Francis Cano, Ph.D. -0- -0- 4,901 -0- -0- -0- -0- -0- 4901
2010-09-29 Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2010. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2010 the compensation committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... DIRECTOR COMPENSATION ... Francis Cano, Ph.D Option Awards ($) 3,677 Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) -3,500 Total ($) 177
2011-09-28 Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2011. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2011 the compensation committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2011. ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Option Awards ($) 7,672 Total ($) 7,672
2012-09-28 Francis R. Cano, Ph.D. 65 1999 Director, Member of Audit Committee,Member of Compensation Committee ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2012. Name Fees Earned or Paid in Cash ($) Stock Awards ($) Option Awards ($) Non-Equity Incentive Plan Compensation ($) Change in Pension Value and Nonqualified Deferred Compensation Earnings All Other Compensation ($) Total ($) Francis Cano, Ph.D -0- -0- 6,661 -0- -0- -0- 6,661
2013-09-30 Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. ... The Audit Committee met one time during fiscal 2013. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. ... During fiscal 2013, the Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano. ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2013. ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Total ($) -0-.
2014-09-29 Francis R. Cano, Ph.D., has served as a Director of the Company since June 1999. The Audit Committee met one time during fiscal 2014. The members of the Audit Committee are Mr. Barbieri and Dr. Cano. The Compensation Committee was comprised of Mr. Allen Barbieri and Dr. Francis Cano.
2015-09-28 Francis R. Cano, Ph.D., 68, Director, Member of Audit Committee and Member of Compensation Committee. Director compensation: $24,599 in 2015.
2016-09-28 Francis R. Cano, Ph.D. 69 1999 Director, Member of Audit Committee, Compensation Committee and Nominating Committee ... The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2016 ... Francis Cano, Ph.D Fees Earned or Paid in Cash ($) -0- Option Awards ($) 21,315 Total ($) 21,315
2017-09-28 Francis R. Cano, Ph.D., 70, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. No cash compensation; no compensation reported for 2017.
2018-09-28 Francis R. Cano, Ph.D., 74, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. Total compensation for fiscal 2018 was $50,293.
2019-09-24 The following table sets forth the name and current age of each nominee for director, the year he or she was first elected a director and his or her position(s) with the Company. The Company does not pay a fee to any third party to identify potential nominees. The Board has not received recommended nominees from a stockholder. ...

Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors.

     The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019.

- 10 -

DIRECTOR COMPENSATION

         Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors.

     The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019.

- 10 -

DIRECTOR COMPENSATION

Name

Age

Director Since

Positions Held

Francis R. Cano, Ph.D.

75

1999

Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee

...

(1) All outside directors each received a 35,000 share stock option grant in fiscal 2019 except for Allen Barbieri, who received a 50,000 share stock option grant. The options were granted at the exercise price of $2.25 per share (market value on the date of grant). The grants for 35,000 were valued at $42,770 and the option for 50,000 was valued at $61,100 using the Black-Scholes options-pricing model (which uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term and the risk-free interest rate).

Name

Fees Earned or Paid in Cash

($)

Stock Awards

($)

Option Awards

($)

Non-Equity Incentive Plan Compensation

($)

Change in Pension Value and Nonqualified Deferred Compensation Earnings

All Other Compensation

($)

Total

($)

Allen Barbieri

-0-

-0-

61,100

-0-

-0-

-0-

-0-

61,100

Francis Cano, Ph.D

-0-

-0-

42,770

-0-

-0-

-0-

42,770

2020-09-25 Francis R. Cano, Ph.D., 76, Director, Member of Compensation Committee and Chairman of Nominating and Corporate Governance Committee. Compensation: $46,020 in fiscal 2020.

Celldex Therapeutics, Inc.

Filing Date Source Excerpt
2006-04-19 Francis R. Cano, Ph.D. Dr. Cano is currently President of Cano Biotechnology Corporation. ... Directors who are not employees of AVANT are each entitled to receive a retainer fee of $15,000 each fiscal year.
2007-04-20 Francis R. Cano, Ph.D. Dr. Cano is currently President of Cano Biotechnology Corporation... The Board of Directors has established a Compensation Committee consisting of J. Barrie Ward, Chairman, Karen Shoos Lipton, Francis Cano and Alf Lindberg. ... The Board of Directors has established a Nominating and Corporate Governance Committee consisting of Karen Shoos Lipton, Chairman, Francis Cano and Alf Lindberg.

DYNAVAX TECHNOLOGIES CORP

Filing Date Source Excerpt
2012-04-25 Francis R. Cano, Ph.D. 67 Director ... Our Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal 2011 for each of the Board committees: Francis R. Cano, Ph.D. X X ... The following table shows for the fiscal year ended December 31, 2011 certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. $40,500 $22,846 $63,346
2013-04-29 Francis R. Cano, Ph.D. 68 Director ... The following table shows for the fiscal year ended December 31, 2012, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. Fees Earned or Paid in Cash $164,500 Options and Awards Granted $183,419 Total $347,919 ... The Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and Cano.
2014-04-28 Francis R. Cano, Ph.D. 69 Director ... Our Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee ... The following table shows for the fiscal year ended December 31, 2013, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. Fees Earned or Paid in Cash $48,500 Options and Awards Granted $44,625 Total $93,125
2015-04-21 Francis R. Cano, Ph.D. 70 Director ... Dr. Cano was appointed to our Board in November 2009. ... The following table shows for the fiscal year ended December 31, 2014, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. $52,000 fees earned or paid in cash, $22,901 options and awards, total $74,901.
2016-04-22 Francis R. Cano, Ph.D. 71 Director ... The Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and Cano ... Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee ... The following table shows for the fiscal year ended December 31, 2015, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. $52,000 Fees Earned or Paid in Cash, $232,955 Option Awards, $284,955 Total.
2017-04-21 Francis R. Cano, Ph.D. 72 Director ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Cano and Kisner ... The following table shows for the fiscal year ended December 31, 2016, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. $52,000 Fees Earned or Paid in Cash, $70,692 Option Awards, $122,692 Total.
2017-07-10 Francis R. Cano, Ph.D., Director
2018-04-20 Francis R. Cano, Ph.D. 73 Director ... Our Compensation Committee is composed of three directors: Ms. Phillips (Chairperson) and Drs. Kisner and Cano ... The following table shows for the fiscal year ended December 31, 2017, certain information with respect to the compensation of all non-employee directors of the Company: Francis R. Cano, Ph.D. $52,000 $29,203 $81,203
2019-04-22 Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in 2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director's death, resignation or removal. We have a policy encouraging our directors' attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of "Withhold" votes than "For" votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled "Corporate Governance." If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: Name Audit Compensation Nominating Francis R. Cano, Ph.D. X X ... The following table shows for the fiscal year ended December 31, 2018, certain information with respect to the compensation of all non-employee directors of the Company: Name Fees Earned or Paid in Cash Option Awards Total Francis R. Cano, Ph.D. $ 52,000 $ 156,767 $ 208,767
2020-04-17 Francis R. Cano, Ph.D. Dr. Cano was appointed to our Board in November 2009. Dr. Cano has been President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business, since 1996 and also serves on the board of Biomerica, Inc., a developer and manufacturer of diagnostic products. Previously, Dr. Cano served on the board of Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr. Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, including as its Vice President and General Manager of the Biologicals unit. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John’s University. The Board believes that Dr. Cano’s experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to serve as a director.
2021-04-16 Francis R. Cano, Ph.D. Dr. Cano was appointed to our Board in November 2009. ... The Board believes that Dr. Cano’s experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to be nominated as a director. ... The following table shows for the fiscal year ended December 31, 2020, certain information with respect to the cash compensation of all non-employee directors of the Company: ... Francis R. Cano, Ph.D. Fees Earned or Paid in Cash $49,212, Option Awards $83,168, Total $132,380.
2022-04-14 Dr. Cano has been a member of our Board since November 2009. Dr. Cano has been President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business, since 1996 and also serves on the board of Biomerica, Inc., a developer and manufacturer of diagnostic products... We believe that Dr. Cano’s experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to serve as a director.
2023-04-13 Francis R. Cano, Ph.D. Dr. Cano has been a member of our Board since November 2009. ... The Board believes that Dr. Cano’s experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to serve as a director.
2024-04-11 Francis R. Cano, Ph.D. Dr. Cano has been a member of our Board since November 2009. ... The Board believes that Dr. Canos experience as a founder of and advisor to established vaccine businesses provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to be nominated as a director.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22